

“  
One of the world’s most renowned  
corporate law specialists with a deep  
involvement in and understanding of IP  
and the life sciences sector. Routinely  
handles market-changing transactions  
of great value and complexity.

Chambers UK, 2016 (Life Sciences)  
”

SLAUGHTER AND MAY

Life Sciences

Slaughter and May has a wide-ranging Life Sciences and healthcare practice which provides the full range of legal advice to pharmaceutical, biotechnology and healthcare companies in this sector. Our clients range from large and medium sized companies to universities and emergent biotechnology ventures. We also advise research institutions and investors in the field. This blend of activity provides us with an unparalleled perspective of the sector.

Our experience derives from providing a wide variety of advice. Slaughter and May has extensive experience in advising on mergers and acquisitions, joint ventures and flotations in the sector. We also provide specialist advice in areas such as tax and environment and have experience in dealing with competition issues in the sector arising out of transactions from licences to mergers. Our intellectual property lawyers play a key role in advising in the sector.

**Slaughter and May is ‘exceptional  
in speed, competence  
and practicality’.**

Legal 500, UK 2015 (Pharmaceuticals and Biotechnology)

## Contents

- 3 Our expertise
- 4 Overview of Slaughter and May
- 5 A genuinely global service
- 6 Sector experience
- 8 Key contacts

# Our expertise /

Our Life Sciences practice deals with a wide range of commercial agreements including licensing, collaboration, research and development agreements and provides strategic advice in managing and commercialising patent and trade mark portfolios. We have considerable experience in advising clients on the exploitation, defence and enforcement of their IP rights including patents, confidential information, rights in databases and software and brands and regulatory issues.

We look for early opportunities to resolve disputes through negotiation, mediation or other ADR. The firm deals with disputes in a wide range of fora including the High Court, Court of Appeal, EPO and other registries and arbitration. We have particular expertise in advising on cross-border litigation and international strategies.

Our group includes lawyers with medical or scientific backgrounds.

We take an active interest in the issues that affect the sector. For example, members of the firm sit on the IP Advisory Committee of the BioIndustry Association (“BIA”), the industry association for biotechnology companies and the editorial board of the Bio-Science Law Review.

# Overview of Slaughter and May /

Slaughter and May is a leading international law firm recognised throughout the business community for its commercial awareness and commitment to clients. We have a diverse and extensive international practice advising on the full range of commercial, financing and other matters. We have a commitment to delivering top quality legal advice, combined with commercial awareness and a “can do” approach.

Central to our culture is the priority we place on the individual needs of our clients. We are organised to be client focused rather than product focused. We develop strong working and personal relationships with our clients and take a proactive approach.

We add value by:

- creating innovative solutions to problems
- giving leading edge structural advice and risk analysis
- understanding what may, or may not, be acceptable in the market
- providing first class case management assistance
- ensuring delivery against realistic timetables and milestones.

**I was very impressed - the deal was highly confidential and highly complex. On an accelerated timeline, they did an incredible job [...] the associates are shockingly bright and they work well together as a coherent team.**

Chambers UK, 2016 (Life Sciences)

**Another key factor which leads clients towards this firm is the sheer depth of experience many of its lead partners have in this field.**

Chambers UK, 2013 (Life Sciences)

**Slaughter and May has ‘an ability not just to identify potential issues, but also to propose creative solutions to them’.**

Legal 500, UK 2013 (Pharmaceuticals and Biotechnology)

# A genuinely global service /

Many of the cases and transactions on which we advise in the sector have a significant cross-border or multi-national aspect. We act as lead counsel on international transactions and we frequently advise pharmaceutical clients on multijurisdictional patent issues working with specialists in other jurisdictions to develop a global strategy.

We provide cross-jurisdictional legal advice that genuinely reflects what 'global' means for our clients. We develop extensive and meaningful relationships with market leading firms from around the world, working with them as a single united team.

We work with like-minded experts in their own jurisdictions who have a depth of understanding that cannot be replicated, but can be shared. The level of communication and understanding between firms and with clients runs deep. Between firms we have made long-term investments to help foster connections at all levels, including investing in joint training, know-how and secondment programmes.

Together, we believe that we can offer the most incisive advice available, no matter how complicated the cross-border issue, whilst always providing value for money.

**A leading corporate practice with profound understanding of the sector's peculiarities and trusted by its giants for industry-defining transactions.**

Chambers UK, 2015 (Life Sciences)

**Slaughter and May provide[s] a high quality service both domestically and internationally, including in a number of the world's emerging markets where it is enjoying an increasingly active presence.**

Chambers UK, 2012 (Life Sciences)

**“They're able to draft agreements in a way that brings clarity to the situation. I like their ability to cover all eventualities, known and unknown.”**

Chambers UK, 2014 (Life Sciences)

# Sector experience /

The following list is intended to give a brief indication of our experience in advising clients in this sector.

- Successfully acting for **Speciality Fibres and Materials** in High Court and Court of Appeal proceedings involving Smith & Nephew and ConvaTec concerning multiple patents and a range of other IP rights
- Advising **GlaxoSmithKline** on its major three part inter-conditional transaction with Novartis involving combining their consumer healthcare, oncology and vaccines businesses
- Advising **Shire plc** in relation to its acquisition of NPS Pharmaceuticals Inc
- Advising **GlaxoSmithKline** on its strategic collaborations with the Aspen Group in Japan, South Africa and Sub-Saharan Africa
- Advising **Reckitt Benckiser** on its demerger to form Indivior PLC, a new listed company focused on pharmaceuticals
- Advising **ThermoFisher** on competition aspects of its US\$13.6 billion acquisition of Life Technologies, combining two world leading laboratory and life sciences companies
- Advising **GlaxoSmithKline** on the divestment to Novartis of its rights in ofatumumab for auto-immune indications for up to US\$1 billion
- Advising **Covidien plc** on EU merger control aspects of the proposed agreed takeover by Medtronic Inc.
- Advising **GlaxoSmithKline** in relation to the pharmaceutical sector inquiry conducted by the European Commission
- Advising **ThermoFisher** on its agreement to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare, a unit of General Electric Company, for approximately US\$1.06 billion
- Advising **GlaxoSmithKline** on its agreement with Pfizer to create a new world-leading HIV company ViiV Healthcare and the subsequent admission of Shinogi
- Advising **Sanofi-Aventis** on the recommended offer for UK-based vaccines company, Acambis
- Advising **GlaxoSmithKline** on its sale to Perrigo of a leading portfolio of over-the-counter products such as Niquitin and Coldrex
- Advising **GE Healthcare Life Sciences Limited**, on the acquisition of Whatman plc, a global supplier of filtration technology and separation products, for approximately £363 million
- Advising **Actelion** on various transactions
- Advising **Biovail Corporation**, on its agreement to acquire worldwide development and commercialisation and IP rights of tetrabenazine products
- Advising **Thermo Fisher Scientific** on competition law aspects of its acquisition of Dionex Corporation
- Advising **GlaxoSmithKline** on the divestment of non-core Healthcare OTC products in the United States and Canada, Europe and other international markets
- Advising **Elekta**, a company focussed on innovation in treating cancer and brain disorders, on its acquisition of Nucletron BV
- Advising **Lonza**, a leading supplier to the lifesciences industries on the financing of its acquisition of Arch Chemicals

- Our London and Hong Kong offices advising **Bupa** on the acquisition of Quality HealthCare Medical Services, the largest private clinic network in Hong Kong, for US\$355 million
- Advising **Parexel International Corporation** on its bid for the acquisition of ClinPhone plc
- Advising **GlaxoSmithKline** on a number of investments in developing markets including the acquisitions from UCB S.A. and Bristol Myers Squibb
- Advising **BOC Edwards** on the disposal of its pharmaceutical systems business
- Advising **Getinge AG**, one of the world's leading providers of equipment and systems to the healthcare industry, on its acquisition of Huntleigh Technology plc
- Advising **Sygen International** on a recommended cash offer by Genus which valued Sygen at approximately £187 million
- Advising a **major plc** in relation to contentious legal and regulatory issues arising from the establishment of a scheme to supply prescription only drugs
- Advising **Stem Cells Inc** in relation to a stem cell cross licence between Stem Cells Inc and ReNeuron Limited and acquisition by Stem Cells Inc of an equity interest in ReNeuron Group plc
- Advising **Cephalon** on its acquisition of all the outstanding share capital of Zeneus Holdings
- Advising a **leading international pharmaceutical company** on a licensing dispute and renegotiation of a major technology licence
- Advising **Shire** on its acquisition of Transkaryotic Therapies, a US based biopharmaceutical company

# Key contacts /

For further information on any pharmaceuticals, biotechnology and healthcare related matter, please contact your usual Slaughter and May contact, or any of the following:

## Intellectual property



**Susie Middlemiss**

T +44 (0)20 7090 4038

E [susie.middlemiss@slaughterandmay.com](mailto:susie.middlemiss@slaughterandmay.com)

## Corporate



**Nilufer von Bismarck**

T +44 (0)20 7090 3186

E [nilufer.vonbismarck@slaughterandmay.com](mailto:nilufer.vonbismarck@slaughterandmay.com)



**David Johnson**

T +44 (0)20 7090 3385

E [david.johnson@slaughterandmay.com](mailto:david.johnson@slaughterandmay.com)



**Simon Nicholls**

T +44 (0)20 7090 3372

E [simon.nicholls@slaughterandmay.com](mailto:simon.nicholls@slaughterandmay.com)

Slaughter and May fields a ‘very knowledgeable’ group which is jointly headed by litigator Susie Middlemiss and corporate and commercial lawyer David Johnson.

Legal 500, UK 2015 (Pharmaceuticals and Biotechnology)